BARCELONA, Spain I January 17, 2024 I La Merie Publishing released its newest product reviewing the pipeline of anti-GPC3 immunotherapeutics in R&D:
GPC3-Targeted Immunotherapy Pipeline Review
Target: Glypican 3; GPC3
Product Category: Antibody; Cells; Radiopharmaceuticals; RNA
This product provides basic information on immunotherapeutics in R&D targeting GPC33.
This product consists of:
- Competitors described in a tabular format covering drug code/INN, target(s)/MoA, class of compound, product category, indication(s) & R&D stage.
- Project History with links to source of information (press release, homepage, abstracts, presentations, annual reports etc).
- One-month online access to La Merie Publishing’s database for immunotherapeutics targeting GPC3 (prerequisite: access to internet).
This product is delivered on the very same day of purchase by e-mail containing competitor and project history reports in pdf format and database credentials. Reports are prepared on the same day.
GPC3, a GPI-anchored cell surface heparan sulfate proteoglycan, is an attractive target for hepatocellular carcinoma (HCC) immunotherapy because it is selectively expressed on HCC and promotes HCC cell growth and migration. GPC3 is rarely or not expressed in normal liver tissues, making it a perfect diagnostic and treatment target for HCC.
Liver cancer is the second leading cause of cancer-related deaths, and hepatocellular carcinoma is the most common type. Therefore, molecular targets are urgently required for the early detection of HCC and the development of novel therapeutic approaches. Glypican-3 (GPC3), an oncofetal proteoglycan anchored to the cell membrane, is normally detected in the fetal liver but not in the healthy adult liver. However, in HCC patients, GPC3 is overexpressed at both the gene and protein levels, and its expression predicts a poor prognosis.
GPC3 has been demonstrated as a viable target for CAR T-cell and NK cell therapy, T-cell engaging bispecific antibodies, immune checkpoint bispecific antibodies, antibody-drug conjugates and radiopharmaceuticals.
The report “GPC3-Targeted Immunotherapy Pipeline Review” can be acquired at La Merie Publishing’s online store: https://lamerie.com/report/gpc3-targeted-immunotherapy-pipeline-review/
About La Merie Publishing
La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. La Merie Publishing prepares brief and full reports. La Merie Publishing products can be purchased in the online store www.lamerie.com and from selected Resellers.
La Merie Publishing offers the service of custom report preparation for corporate clients, including, but not limited to, pipeline analysis reports, drug profiles and any other competitive intelligence elaboration of interest.
SOURCE: La Merie Publishing
Post Views: 467
BARCELONA, Spain I January 17, 2024 I La Merie Publishing released its newest product reviewing the pipeline of anti-GPC3 immunotherapeutics in R&D:
GPC3-Targeted Immunotherapy Pipeline Review
Target: Glypican 3; GPC3
Product Category: Antibody; Cells; Radiopharmaceuticals; RNA
This product provides basic information on immunotherapeutics in R&D targeting GPC33.
This product consists of:
- Competitors described in a tabular format covering drug code/INN, target(s)/MoA, class of compound, product category, indication(s) & R&D stage.
- Project History with links to source of information (press release, homepage, abstracts, presentations, annual reports etc).
- One-month online access to La Merie Publishing’s database for immunotherapeutics targeting GPC3 (prerequisite: access to internet).
This product is delivered on the very same day of purchase by e-mail containing competitor and project history reports in pdf format and database credentials. Reports are prepared on the same day.
GPC3, a GPI-anchored cell surface heparan sulfate proteoglycan, is an attractive target for hepatocellular carcinoma (HCC) immunotherapy because it is selectively expressed on HCC and promotes HCC cell growth and migration. GPC3 is rarely or not expressed in normal liver tissues, making it a perfect diagnostic and treatment target for HCC.
Liver cancer is the second leading cause of cancer-related deaths, and hepatocellular carcinoma is the most common type. Therefore, molecular targets are urgently required for the early detection of HCC and the development of novel therapeutic approaches. Glypican-3 (GPC3), an oncofetal proteoglycan anchored to the cell membrane, is normally detected in the fetal liver but not in the healthy adult liver. However, in HCC patients, GPC3 is overexpressed at both the gene and protein levels, and its expression predicts a poor prognosis.
GPC3 has been demonstrated as a viable target for CAR T-cell and NK cell therapy, T-cell engaging bispecific antibodies, immune checkpoint bispecific antibodies, antibody-drug conjugates and radiopharmaceuticals.
The report “GPC3-Targeted Immunotherapy Pipeline Review” can be acquired at La Merie Publishing’s online store: https://lamerie.com/report/gpc3-targeted-immunotherapy-pipeline-review/
About La Merie Publishing
La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. La Merie Publishing prepares brief and full reports. La Merie Publishing products can be purchased in the online store www.lamerie.com and from selected Resellers.
La Merie Publishing offers the service of custom report preparation for corporate clients, including, but not limited to, pipeline analysis reports, drug profiles and any other competitive intelligence elaboration of interest.
SOURCE: La Merie Publishing
Post Views: 467
